Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2024; 30(28): 3447-3451
Published online Jul 28, 2024. doi: 10.3748/wjg.v30.i28.3447
Exploring non-invasive diagnostics for metabolic dysfunction-associated fatty liver disease
Biao Qu, Zheng Li
Biao Qu, Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China
Zheng Li, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, Xuzhou 221000, Jiangsu Province, China
Author contributions: Li Z designed the article; Qu B and Li Z drafted and revised the article.
Supported by The National Natural Science Foundation of China, No. 82104525.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng Li, PhD, Lecturer, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com
Received: April 24, 2024
Revised: July 1, 2024
Accepted: July 8, 2024
Published online: July 28, 2024
Processing time: 90 Days and 9 Hours
Core Tip

Core Tip: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a bur-densome public health problem. The diagnostic assessment of MAFLD is an important step for timely management. Extensive effort and encouraging progress have been made to establish non-invasive tests to diagnose steatohepatitis and fibrosis.